Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IART
stocks logo

IART

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
432.89M
-2.2%
0.800
-17.48%
392.15M
+2.48%
0.488
+19.12%
426.67M
+2.66%
0.552
+22.7%
Estimates Revision
The market is revising Downward the revenue expectations for Integra LifeSciences Holdings Corporation (IART) for FY2025, with the revenue forecasts being adjusted by -2.11% over the past three months. During the same period, the stock price has changed by -15.13%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.51%
In Past 3 Month
Stock Price
Go Down
down Image
-15.13%
In Past 3 Month
Wall Street analysts forecast IART stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IART stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
4 Sell
Moderate Sell
Current: 13.570
sliders
Low
10.00
Averages
12.33
High
14.00
Current: 13.570
sliders
Low
10.00
Averages
12.33
High
14.00
Truist
Hold
downgrade
$15 -> $13
2025-11-03
Reason
Truist
Price Target
$15 -> $13
2025-11-03
downgrade
Hold
Reason
Truist lowered the firm's price target on Integra LifeSciences to $13 from $15 and keeps a Hold rating on the shares. The firm notes it was surprised to see a Q3 revenue miss following multiple rebased outlooks, including last quarter. The intra-quarter issues impacted the business and more than overshadowed progress made on profitability and free cash flow, the analyst tells investors in a research note.
JPMorgan
Robbie Marcus
Underweight
maintain
$12 -> $13
2025-10-31
Reason
JPMorgan
Robbie Marcus
Price Target
$12 -> $13
2025-10-31
maintain
Underweight
Reason
JPMorgan analyst Robbie Marcus raised the firm's price target on Integra LifeSciences to $13 from $12 and keeps an Underweight rating on the shares. The firm updated the company's model.
Citi
Sell
downgrade
$12 -> $11
2025-10-31
Reason
Citi
Price Target
$12 -> $11
2025-10-31
downgrade
Sell
Reason
Citi lowered the firm's price target on Integra LifeSciences to $11 from $12 and keeps a Sell rating on the shares.
Truist
Hold
maintain
$13 -> $15
2025-10-15
Reason
Truist
Price Target
$13 -> $15
2025-10-15
maintain
Hold
Reason
Truist raised the firm's price target on Integra LifeSciences to $15 from $13 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects "healthy" Q3 revenue and earnings across its coverage but also braces for "stock volatility", with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on "cleaner" names where there is less perceived controversy heading into the quarter.
Citizens JMP
Outperform
downgrade
$35 -> $25
2025-05-09
Reason
Citizens JMP
Price Target
$35 -> $25
2025-05-09
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on Integra LifeSciences to $25 from $35 and keeps an Outperform rating on the shares. Integra's Q1 sales and earnings results were within guidance ranges, but expectations for Q2 were a bit below, the analyst tells investors in a research note. The firm views Monday's 20% selloff on this news as overdone.
Truist Securities
Richard Newitter
Hold
Maintains
$26 → $19
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$26 → $19
2025-04-11
Maintains
Hold
Reason
Truist lowered the firm's price target on Integra LifeSciences to $19 from $26 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Integra Lifesciences Holdings Corp (IART.O) is 5.68, compared to its 5-year average forward P/E of 14.44. For a more detailed relative valuation and DCF analysis to assess Integra Lifesciences Holdings Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
14.44
Current PE
5.68
Overvalued PE
20.19
Undervalued PE
8.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.40
Undervalued EV/EBITDA
9.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.29
Current PS
0.00
Overvalued PS
3.42
Undervalued PS
1.16
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IART News & Events

Events Timeline

(ET)
2025-11-25
08:43:27
Integra Applauds Policy Improvements Enhancing Access for Medicare Beneficiaries
select
2025-11-11 (ET)
2025-11-11
16:42:43
Integra Receives FDA Approval for Cusa Clarity Ultrasonic Surgical Aspirator
select
2025-10-30 (ET)
2025-10-30
06:05:33
Integra LifeSciences Projects Q4 EPS Between 79c and 84c, Below Consensus of 92c
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-12NASDAQ.COM
Integra LifeSciences Obtains FDA Approval for Cardiac Application of CUSA Clarity System

  • FDA Clearance: Integra LifeSciences received U.S. FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System, expanding its use to cardiac surgery for debridement during valve replacement and repair procedures.

  • Existing Approvals: The CUSA Clarity system is already approved for various surgical fields, including neurosurgery and orthopedic surgery, where it aids in the fragmentation and aspiration of soft and hard tissues.

  • Significance of Clearance: This new clearance is a significant milestone, allowing for the application of ultrasonic aspiration in delicate cardiovascular surgeries, supported by sufficient safety and performance data.

  • Upcoming Showcase: Integra will present the CUSA Clarity system at the American Association for Thoracic Surgeon Mitral Valve Conclave in New York City on December 11-12, 2025, emphasizing its expanded role in cardiac care.

[object Object]
Preview
4.0
11-01Benzinga
JP Morgan Keeps Underweight Rating on Integra Lifesciences, Increases Price Target to $13

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.

  • Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.

[object Object]
Preview
9.5
10-30NASDAQ.COM
Integra LifeSciences Reports Reduced Q3 Loss; Lowers FY25 Revenue Forecast; Shares Rise

  • Quarterly Performance: Integra LifeSciences reported a narrower loss of $5.40 million for Q3, improving from a $10.69 million loss last year, with revenues rising to $402.06 million.

  • Earnings Exceed Expectations: The company posted earnings of $41.6 million or $0.54 per share, surpassing analyst expectations of $0.43 per share.

  • Revised Revenue Guidance: Integra lowered its fiscal 2025 revenue guidance to a range of $1.620 billion to $1.640 billion, reflecting a growth adjustment from previous estimates.

  • Stock Market Reaction: Following the earnings report, Integra's stock was trading down 7.84% at $14.22 in premarket activity.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Integra Lifesciences Holdings Corp (IART) stock price today?

The current price of IART is 13.57 USD — it has increased 0.59 % in the last trading day.

arrow icon

What is Integra Lifesciences Holdings Corp (IART)'s business?

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

arrow icon

What is the price predicton of IART Stock?

Wall Street analysts forecast IART stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Integra Lifesciences Holdings Corp (IART)'s revenue for the last quarter?

Integra Lifesciences Holdings Corp revenue for the last quarter amounts to 402.06M USD, increased 5.57 % YoY.

arrow icon

What is Integra Lifesciences Holdings Corp (IART)'s earnings per share (EPS) for the last quarter?

Integra Lifesciences Holdings Corp. EPS for the last quarter amounts to -0.07 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Integra Lifesciences Holdings Corp (IART)'s fundamentals?

The market is revising Downward the revenue expectations for Integra LifeSciences Holdings Corporation (IART) for FY2025, with the revenue forecasts being adjusted by -2.11% over the past three months. During the same period, the stock price has changed by -15.13%.
arrow icon

How many employees does Integra Lifesciences Holdings Corp (IART). have?

Integra Lifesciences Holdings Corp (IART) has 4396 emplpoyees as of December 05 2025.

arrow icon

What is Integra Lifesciences Holdings Corp (IART) market cap?

Today IART has the market capitalization of 1.06B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free